APRIL 02, 2014
http://www.itbusinessnet.com/article/Bioheart-to-Present-at-SELECTBIO-Clinical-Translation-of-Stem-Cells--3160980
SUNRISE, FL -- (Marketwired) -- 04/02/14 -- Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that it will present at the SELECTBIO 2nd Annual Clinical Translation of Stem Cells on April 21st, 2014. The conference brings together basic scientists, clinician-scientists, as well as medical practitioners/surgeons focusing on studying, characterizing, and deploying various classes of stem cells for therapeutic utility.
Kristin Comella, Bioheart's Chief Scientific Officer, will present a summary of data on the use of stem cells to treat a variety of indications. She will also provide a live demonstration in the "hands-on" clinical practicum. SELECTBIO has partnered with surgeons and a surgery center in the Palm Springs area to offer conference delegates the ability to observe adipose tissue extraction and processing ex vivo in real time.
This "hands-on" demonstration led by leading surgeons in the field is in full compliance with applicable laws and regulations and performed by board-certified surgeons. This conference therefore provides valuable learning and networking experiences for both basic researchers and clinicians alike seeking the most up-to-date information, protocols, and products in this emerging field.
About Bioheart, Inc.
Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.
Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.
http://www.itbusinessnet.com/article/Bioheart-to-Present-at-SELECTBIO-Clinical-Translation-of-Stem-Cells--3160980
SUNRISE, FL -- (Marketwired) -- 04/02/14 -- Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that it will present at the SELECTBIO 2nd Annual Clinical Translation of Stem Cells on April 21st, 2014. The conference brings together basic scientists, clinician-scientists, as well as medical practitioners/surgeons focusing on studying, characterizing, and deploying various classes of stem cells for therapeutic utility.
Kristin Comella, Bioheart's Chief Scientific Officer, will present a summary of data on the use of stem cells to treat a variety of indications. She will also provide a live demonstration in the "hands-on" clinical practicum. SELECTBIO has partnered with surgeons and a surgery center in the Palm Springs area to offer conference delegates the ability to observe adipose tissue extraction and processing ex vivo in real time.
This "hands-on" demonstration led by leading surgeons in the field is in full compliance with applicable laws and regulations and performed by board-certified surgeons. This conference therefore provides valuable learning and networking experiences for both basic researchers and clinicians alike seeking the most up-to-date information, protocols, and products in this emerging field.
About Bioheart, Inc.
Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.
Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.